标签归档：phosphate

多肽定制Phosphate Acceptor Peptide 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Phosphate Acceptor Peptide
编码
别名 Phosphate Acceptor Peptide
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） RRKASGPPV
序列（三字母缩写） H-Arg-Arg-Lys-Ala-Ser-Gly-Pro-Pro-Val-OH (trifluoroacetate salt)
基本描述
溶解度
分子量 967.2
化学式 C41H74N16O11
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Phosphate Acceptor Peptide 编码
Figures Phosphate Acceptor Peptide 编码
Reference C.A. O’Brian el al., BBRC, 124, 296 (1984)
C端
N端
化学桥

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Chloroquine-d4 phosphate (Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate 是 Chloroquine phosphate 的氘代物。Chloroquine phosphate 是一种广泛用于疟疾和类风湿性关节炎的抗疟疾和抗炎剂。Chloroquine phosphate 是 autophagy 和 toll-like receptors (TLRs) 的抑制剂。Chloroquine phosphate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (E

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Chloroquine-d4 phosphate is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

519.89

Formula

C18H28D4ClN3O8P2
中文名称

磷酸氯喹 d4 (磷酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.

    [3]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.

    [4]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.

    [5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [6]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.

    [7]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Chloroquine-d4 phosphate (Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate 是 Chloroquine phosphate 的氘代物。Chloroquine phosphate 是一种广泛用于疟疾和类风湿性关节炎的抗疟疾和抗炎剂。Chloroquine phosphate 是 autophagy 和 toll-like receptors (TLRs) 的抑制剂。Chloroquine phosphate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (E

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Chloroquine-d4 phosphate is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

519.89

Formula

C18H28D4ClN3O8P2
中文名称

磷酸氯喹 d4 (磷酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.

    [3]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.

    [4]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.

    [5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [6]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.

    [7]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Chloroquine-d4 phosphate (Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate 是 Chloroquine phosphate 的氘代物。Chloroquine phosphate 是一种广泛用于疟疾和类风湿性关节炎的抗疟疾和抗炎剂。Chloroquine phosphate 是 autophagy 和 toll-like receptors (TLRs) 的抑制剂。Chloroquine phosphate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (E

Chloroquine-d4 phosphate(Synonyms: 磷酸氯喹 d4 (磷酸盐))

Chloroquine-d4 phosphate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Chloroquine-d4 phosphate is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

519.89

Formula

C18H28D4ClN3O8P2
中文名称

磷酸氯喹 d4 (磷酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.

    [3]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.

    [4]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.

    [5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [6]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.

    [7]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sphinganine 1-phosphate (Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) 是一种极性鞘脂代谢物，可调节细胞迁移、细胞分化等众多生理过程。

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate Chemical Structure

CAS No. : 19794-97-9

规格 价格 是否有货
1 mg ￥3500 询问价格 & 货期
5 mg ￥10800 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) is a polar sphingolipid metabolite that regulates cell migration, differentiation, survival and complex physiological processes[1].

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Sphinganine 1-phosphate (S1P) is a potent signaling molecule involved in cell stress responses, cancer, angiogenesis and lymphocyte trafficking. Sphinganine 1-phosphate functions primarily by activating a subgroup of the endothelial differentiation gene (EDG) family of G-protein coupled cell surface receptors. Sphinganine 1-phosphate has opposite effects in the regulation of cell metabolism. Sphinganine 1-phosphate regulates skeletal muscle differentiation and regeneration[1].
Sphinganine 1-phosphate (S1P) is involved in cancer. Sphinganine 1-phosphate regulates processes such as inflammation, which can drive tumorigenesis; neovascularization, which provides cancer cells with nutrients and oxygen; and cell growth and survival[1].
Sphinganine-1-Phosphate (1 μM) phosphorylates ERK MAPK, Akt, and HSP27 and induces HSP27 in human renal endothelial cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: Human renal endothelial cells or human kidney proximal tubule (HK-2) cells
Concentration: 1 μM
Incubation Time: 2 or 4 hours
Result: Induced HSP27 mRNA in cultured human renal endothelial cells.
Phosphorylated ERK MAPK and AKT in human renal endothelial cells in a time-dependent manner.
Phosphorylated and induced HSP27.

体内研究
(In Vivo)

Sphinganine 1-phosphate can enhance wound healing in diabetic mice[1]. Sphinganine 1-phosphate provides renal and hepatic protection after liver ischemia and reperfusion (IR) injury in mice through selective activation of S1P1 receptors and pertussis toxin-sensitive G-proteins with subsequent activation of ERK and Akt. Sphinganine 1-phosphate (administered 0.1 mg/kg i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion) protects against hepatic and renal injury after liver IR[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (20-25 g)[2]
Dosage: 0.1 mg/kg
Administration: Administered i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion
Result: The plasma level of alanine aminotransferase (ALT) and Creatinine (Cr) was 80±6 U/L and 0.46±0.05 mg/dL, respectively.
The increases in ALT (7474±557 U/L) and Cr (0.55±0.05 mg/dL) were significantly suppressed at 24 h after reperfusion in mice treated with 0.1 mg/kg i.v. before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion.

分子量

381.49

Formula

C18H40NO5P
CAS 号

19794-97-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Montserrat Serra, et al. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul. 2010;50(1):349-62.

    [2]. Sang Won Park, et al. Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab Invest. 2010 Aug;90(8):1209-24.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sphinganine 1-phosphate (Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) 是一种极性鞘脂代谢物，可调节细胞迁移、细胞分化等众多生理过程。

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate Chemical Structure

CAS No. : 19794-97-9

规格 价格 是否有货
1 mg ￥3500 询问价格 & 货期
5 mg ￥10800 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) is a polar sphingolipid metabolite that regulates cell migration, differentiation, survival and complex physiological processes[1].

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Sphinganine 1-phosphate (S1P) is a potent signaling molecule involved in cell stress responses, cancer, angiogenesis and lymphocyte trafficking. Sphinganine 1-phosphate functions primarily by activating a subgroup of the endothelial differentiation gene (EDG) family of G-protein coupled cell surface receptors. Sphinganine 1-phosphate has opposite effects in the regulation of cell metabolism. Sphinganine 1-phosphate regulates skeletal muscle differentiation and regeneration[1].
Sphinganine 1-phosphate (S1P) is involved in cancer. Sphinganine 1-phosphate regulates processes such as inflammation, which can drive tumorigenesis; neovascularization, which provides cancer cells with nutrients and oxygen; and cell growth and survival[1].
Sphinganine-1-Phosphate (1 μM) phosphorylates ERK MAPK, Akt, and HSP27 and induces HSP27 in human renal endothelial cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: Human renal endothelial cells or human kidney proximal tubule (HK-2) cells
Concentration: 1 μM
Incubation Time: 2 or 4 hours
Result: Induced HSP27 mRNA in cultured human renal endothelial cells.
Phosphorylated ERK MAPK and AKT in human renal endothelial cells in a time-dependent manner.
Phosphorylated and induced HSP27.

体内研究
(In Vivo)

Sphinganine 1-phosphate can enhance wound healing in diabetic mice[1]. Sphinganine 1-phosphate provides renal and hepatic protection after liver ischemia and reperfusion (IR) injury in mice through selective activation of S1P1 receptors and pertussis toxin-sensitive G-proteins with subsequent activation of ERK and Akt. Sphinganine 1-phosphate (administered 0.1 mg/kg i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion) protects against hepatic and renal injury after liver IR[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (20-25 g)[2]
Dosage: 0.1 mg/kg
Administration: Administered i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion
Result: The plasma level of alanine aminotransferase (ALT) and Creatinine (Cr) was 80±6 U/L and 0.46±0.05 mg/dL, respectively.
The increases in ALT (7474±557 U/L) and Cr (0.55±0.05 mg/dL) were significantly suppressed at 24 h after reperfusion in mice treated with 0.1 mg/kg i.v. before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion.

分子量

381.49

Formula

C18H40NO5P
CAS 号

19794-97-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Montserrat Serra, et al. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul. 2010;50(1):349-62.

    [2]. Sang Won Park, et al. Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab Invest. 2010 Aug;90(8):1209-24.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sphinganine 1-phosphate (Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) 是一种极性鞘脂代谢物，可调节细胞迁移、细胞分化等众多生理过程。

Sphinganine 1-phosphate(Synonyms: D-erythro-Dihydrosphingosine 1-phosphate)

Sphinganine 1-phosphate Chemical Structure

CAS No. : 19794-97-9

规格 价格 是否有货
1 mg ￥3500 询问价格 & 货期
5 mg ￥10800 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) is a polar sphingolipid metabolite that regulates cell migration, differentiation, survival and complex physiological processes[1].

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Sphinganine 1-phosphate (S1P) is a potent signaling molecule involved in cell stress responses, cancer, angiogenesis and lymphocyte trafficking. Sphinganine 1-phosphate functions primarily by activating a subgroup of the endothelial differentiation gene (EDG) family of G-protein coupled cell surface receptors. Sphinganine 1-phosphate has opposite effects in the regulation of cell metabolism. Sphinganine 1-phosphate regulates skeletal muscle differentiation and regeneration[1].
Sphinganine 1-phosphate (S1P) is involved in cancer. Sphinganine 1-phosphate regulates processes such as inflammation, which can drive tumorigenesis; neovascularization, which provides cancer cells with nutrients and oxygen; and cell growth and survival[1].
Sphinganine-1-Phosphate (1 μM) phosphorylates ERK MAPK, Akt, and HSP27 and induces HSP27 in human renal endothelial cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: Human renal endothelial cells or human kidney proximal tubule (HK-2) cells
Concentration: 1 μM
Incubation Time: 2 or 4 hours
Result: Induced HSP27 mRNA in cultured human renal endothelial cells.
Phosphorylated ERK MAPK and AKT in human renal endothelial cells in a time-dependent manner.
Phosphorylated and induced HSP27.

体内研究
(In Vivo)

Sphinganine 1-phosphate can enhance wound healing in diabetic mice[1]. Sphinganine 1-phosphate provides renal and hepatic protection after liver ischemia and reperfusion (IR) injury in mice through selective activation of S1P1 receptors and pertussis toxin-sensitive G-proteins with subsequent activation of ERK and Akt. Sphinganine 1-phosphate (administered 0.1 mg/kg i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion) protects against hepatic and renal injury after liver IR[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (20-25 g)[2]
Dosage: 0.1 mg/kg
Administration: Administered i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion
Result: The plasma level of alanine aminotransferase (ALT) and Creatinine (Cr) was 80±6 U/L and 0.46±0.05 mg/dL, respectively.
The increases in ALT (7474±557 U/L) and Cr (0.55±0.05 mg/dL) were significantly suppressed at 24 h after reperfusion in mice treated with 0.1 mg/kg i.v. before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion.

分子量

381.49

Formula

C18H40NO5P
CAS 号

19794-97-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Montserrat Serra, et al. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul. 2010;50(1):349-62.

    [2]. Sang Won Park, et al. Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab Invest. 2010 Aug;90(8):1209-24.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dextran, phosphate Cat. No. DX70-PA-1 70 kD 50 mg修饰性聚乙二醇

发表于由

上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

Dextran, phosphate

Cat. No. DX70-PA-1
Specification 70 kD
Unit Size 50 mg
Price $425.00

Qty Add to Cart

Similar names: Dextran phosphorylated; Phosphate dextran; Phosphorylated dextran

Product Specifications:

  • Appearance (form): Solid;
  • Appearance (color): White/off-white;
  • Functional groups: Phosphate;
  • Charge: Negative;

Storage:

  • Store at room temperature.

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Carvedilol phosphate hemihydrate (Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) 是一种非选择性 β/α-1 受体阻断剂。Carvedilol 抑制脂质过氧化，IC50 为 5 μM。Carvedilol 是一种多用途降压剂，有潜力用于心绞痛和充血性心力衰竭的研究。Carvedilol是一种自噬 (autophagy) 诱导剂，可抑制 NLRP3 炎性体。

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate Chemical Structure

CAS No. : 610309-89-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Carvedilol phosphate hemihydrate 的其他形式现货产品:

Carvedilol (S)-Carvedilol (R)-Carvedilol

生物活性

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker[1]. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

IC50 & Target

β/α-1 adrenergic receptor[1]
IC50: 5 μM (lipid peroxidation)[2]
Autophagy[3]
体外研究
(In Vitro)

Superoxide generation by activated human neutrophils in vitro is inhibited by Carvedilol with an IC50 of 28 μM. Carvedilol is shown to scavenge oxygen free radicals in a cell-free system with an IC50 of 25 μM[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

513.48

Formula

C24H30N2O8.5P
CAS 号

610309-89-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27(1):19-22.

    [2]. Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11(4):S41-8.

    [3]. Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Carvedilol phosphate hemihydrate (Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) 是一种非选择性 β/α-1 受体阻断剂。Carvedilol 抑制脂质过氧化，IC50 为 5 μM。Carvedilol 是一种多用途降压剂，有潜力用于心绞痛和充血性心力衰竭的研究。Carvedilol是一种自噬 (autophagy) 诱导剂，可抑制 NLRP3 炎性体。

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate Chemical Structure

CAS No. : 610309-89-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Carvedilol phosphate hemihydrate 的其他形式现货产品:

Carvedilol (S)-Carvedilol (R)-Carvedilol

生物活性

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker[1]. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

IC50 & Target

β/α-1 adrenergic receptor[1]
IC50: 5 μM (lipid peroxidation)[2]
Autophagy[3]
体外研究
(In Vitro)

Superoxide generation by activated human neutrophils in vitro is inhibited by Carvedilol with an IC50 of 28 μM. Carvedilol is shown to scavenge oxygen free radicals in a cell-free system with an IC50 of 25 μM[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

513.48

Formula

C24H30N2O8.5P
CAS 号

610309-89-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27(1):19-22.

    [2]. Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11(4):S41-8.

    [3]. Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Carvedilol phosphate hemihydrate (Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) 是一种非选择性 β/α-1 受体阻断剂。Carvedilol 抑制脂质过氧化，IC50 为 5 μM。Carvedilol 是一种多用途降压剂，有潜力用于心绞痛和充血性心力衰竭的研究。Carvedilol是一种自噬 (autophagy) 诱导剂，可抑制 NLRP3 炎性体。

Carvedilol phosphate hemihydrate(Synonyms: BM 14190 phosphate hemihydrate)

Carvedilol phosphate hemihydrate Chemical Structure

CAS No. : 610309-89-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Carvedilol phosphate hemihydrate 的其他形式现货产品:

Carvedilol (S)-Carvedilol (R)-Carvedilol

生物活性

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker[1]. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

IC50 & Target

β/α-1 adrenergic receptor[1]
IC50: 5 μM (lipid peroxidation)[2]
Autophagy[3]
体外研究
(In Vitro)

Superoxide generation by activated human neutrophils in vitro is inhibited by Carvedilol with an IC50 of 28 μM. Carvedilol is shown to scavenge oxygen free radicals in a cell-free system with an IC50 of 25 μM[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

513.48

Formula

C24H30N2O8.5P
CAS 号

610309-89-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27(1):19-22.

    [2]. Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11(4):S41-8.

    [3]. Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Chloroquine phosphate(Synonyms: 磷酸氯喹)

发表于由

Chloroquine phosphate (Synonyms: 磷酸氯喹) 纯度: 99.85%

Chloroquine phosphate 是一种广泛用于疟疾和类风湿性关节炎的抗疟疾和抗炎剂。Chloroquine phosphate 是 autophagy 和 toll-like receptors (TLRs) 的抑制剂。Chloroquine phosphate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC50=1.13 μM)。

Chloroquine phosphate(Synonyms: 磷酸氯喹)

Chloroquine phosphate Chemical Structure

CAS No. : 50-63-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ￥550 In-stock
100 mg ￥500 In-stock
200 mg ￥875 In-stock
500 mg ￥1750 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Chloroquine phosphate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Antiviral Compound Library
  • Autophagy Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Pyroptosis Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Antibiotics Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Antiparasitic Compound library
  • Targeted Diversity Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

IC50 & Target[1][2][3][5]

Malaria

 

TLRs

 

SARS-COV-2

 

HIV-1

 

体外研究
(In Vitro)

Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (CHQ, 20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4+ T cells[1]. Chloroquine (25 μM) suppresses MMP-9 mRNA expression in normoxia and hypoxia in parental MDA-MB-231 cells. Chloroquine has cell-, dose- and hypoxia-dependent effects on MMP-2, MMP-9 and MMP-13 mRNA expression[2]. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly reduces HuH7 cell proliferation in vitro[3].
Chloroquine (0.01-100 μM; 48 hours) potently blocks virus infection (vero E6 cells infected with SARS-CoV-2) at low-micromolar concentration (EC50= 1.13 μM). Chloroquine blocks virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Chloroquine (80 mg/kg, i.p.) does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in the orthotopic mouse model[2]. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly inhibits tumour growth in the mouse xenograft model. HCC development in the DEN/NMOR rat model is also significantly inhibited by chloroquine[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

515.86

Formula

C18H32ClN3O8P2
CAS 号

50-63-5
中文名称

磷酸氯喹；氯喹宁二磷酸盐；氯化喹啉磷酸盐；氯喹磷酸盐；磷酸氯化喹啉；磷酸氯喹啉；二磷酸氯喹；氯喹二磷酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro: 

H2O : ≥ 33 mg/mL (63.97 mM)

DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9385 mL 9.6926 mL 19.3851 mL
5 mM 0.3877 mL 1.9385 mL 3.8770 mL
10 mM 0.1939 mL 0.9693 mL 1.9385 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.

    [2]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.

    [3]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.

    [4]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.

    [5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [6]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.
Cell Assay
[2]

The cells are cultured in 6-well plates with normal culture medium in the presence of vehicle or 25 or 50 μM chloroquine, until near confluency, after which they are rinsed with sterile phosphate-buffered saline (PBS) and cultured further for the indicated times in serum-free culture medium. At the desired time-points, the culture medium is discarded and the cells are quickly harvested in lysis buffer and clarified by centrifugation. Subsequent to boiling the supernatants in reducing sodium dodecyl sulphate (SDS) sample buffer, equal amounts of protein (100 μg) are loaded per lane and the samples are electrophoresed into 10 or 4-20% gradient polyacrylamide SDS gels, then transferred to a nitrocellulose membrane. To detect TLR9, the blots are incubated overnight at 4°C with anti-TLR9 antibodies, diluted 1:500 in Tris-buffered saline with 0.1% (v/v) Tween-20 (TBST). Equal loading is confirmed with polyclonal rabbit anti-actin. Secondary detection is performed with horseradish peroxidase-linked secondary antibodies. The protein bands are visualized by chemiluminescence using an ECL kit.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

Control and TLR9 siRNA MDA-MB-231 cells (5×105 cells in 100 μL) are inoculated into the mammary fat pads of four-week-old, immune-deficient mice (athymic nude/nu Foxn1). Treatments are started seven days after tumor cell inoculation. The mice are treated daily either with intraperitoneal (i.p.) chloroquine (80 mg/kg) or vehicle (PBS). The animals are monitored daily for clinical signs. Tumor measurements are performed twice a week and tumor volume is calculated according to the formula V=(π/6) (d1×d2)3/2, where d1 and d2 are perpendicular tumor diameters. The tumors are allowed to grow for 22 days, at which point the mice are sacrificed and the tumors are dissected for a final measurement. Throughout the experiments, the animals are maintained under controlled pathogen-free environmental conditions (20-21°C, 30-60% relative humidity and a 12-h lighting cycle). The mice are fed with small-animal food pellets and supplied with sterile water ad libitum.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.

    [2]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.

    [3]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.

    [4]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.

    [5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [6]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.

Ruxolitinib phosphate(Synonyms: INCB018424 phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ruxolitinib phosphate (Synonyms: INCB018424 phosphate) 纯度: 99.98%

Ruxolitinib phosphate (INCB018424 phosphate) 是一种有效的 JAK1/2 抑制剂， IC50 分别为3.3 nM/2.8 nM，比JAK3选择性高130倍。

Ruxolitinib phosphate(Synonyms: INCB018424 phosphate)

Ruxolitinib phosphate Chemical Structure

CAS No. : 1092939-17-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
5 mg ￥500 In-stock
10 mg ￥700 In-stock
50 mg ￥1700 In-stock
100 mg ￥3100 In-stock
200 mg ￥5800 In-stock
500 mg ￥12000 In-stock
1 g ￥19000 In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Ruxolitinib phosphate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Therapy Drug Library
  • Mitochondria-Targeted Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

IC50 & Target[1]

JAK2

2.8 nM (IC50)

JAK1

3.3 nM (IC50)

Tyk2

19 nM (IC50)

JAK3

428 nM (IC50)

体外研究
(In Vitro)

Ruxolitinib (INCB018424) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibits the growth of HEL cells with EC50 of 186 nM. Ruxolitinib markedly increases apoptosis in Ba/F3-EpoR-JAK2V617F cell system, and inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Ruxolitinib (180 mg/kg, p.o.) reduces the tumor burden of mice inoculated with JAK2V617F-expressing cells without causing anemia or lymphopenia[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

404.36

Formula

C17H21N6O4P
CAS 号

1092939-17-7
中文名称

鲁索利替尼磷酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : ≥ 31 mg/mL (76.66 mM)

H2O : 10 mg/mL (24.73 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4730 mL 12.3652 mL 24.7304 mL
5 mM 0.4946 mL 2.4730 mL 4.9461 mL
10 mM 0.2473 mL 1.2365 mL 2.4730 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 0.5% MC  0.5% Tween-80

    Solubility: 10 mg/mL (24.73 mM); Suspended solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.75 mg/mL (6.80 mM); Clear solution

  • 3.

    请依序添加每种溶剂： 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.75 mg/mL (6.80 mM); Clear solution

  • 4.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.14 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.14 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 5.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.14 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.14 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 6.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.14 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.14 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.

    [2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31.

    [3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631.
Cell Assay
[1]

Cells are seeded at 2000/well of white bottom 96-well plates, treated with compounds from DMSO stocks (0.2% final DMSO concentration), and incubated for 48 hours at 37°C with 5% CO2. Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent inhibition relative to vehicle control, and IC50 curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Mice are fed standard rodent chow and provided with water ad libitum. Ba/F3-JAK2V617F cells (105 per mouse) are inoculated intravenously into 6- to 8-week-old female BALB/c mice. Survival is monitored daily, and moribund mice are humanely killed and considered deceased at time of death. Treatment with vehicle (5% dimethyl acetamide, 0.5% methocellulose) or Ruxolitinib (INCB018424) begins within 24 hours of cell inoculation, twice daily by oral gavage. Hematologic parameters are measured using a Bayer Advia120 analyzed, and statistical significance is determined using Dunnett testing.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.

    [2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31.

    [3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Uzansertib phosphate(Synonyms: INCB053914 phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Uzansertib phosphate (Synonyms: INCB053914 phosphate) 纯度: 98.44%

Uzansertib (INCB053914) phosphate 是一种具有口服活性的，ATP 竞争性泛-PIM 激酶抑制剂，对于 PIM1，PIM2 和 PIM3 的 IC50 分别为 0.24 nM，30 nM 和 0.12 nM。Uzansertib phosphate 对多种血液肿瘤细胞系具有广泛的抗增殖活性。

Uzansertib phosphate(Synonyms: INCB053914 phosphate)

Uzansertib phosphate Chemical Structure

CAS No. : 2088852-47-3

规格 价格 是否有货 数量
1 mg ￥1200 In-stock
5 mg ￥3600 In-stock
10 mg ￥5400 In-stock
25 mg ￥9800 In-stock
50 mg ￥15000 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Uzansertib phosphate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • Orally Active Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library

生物活性

Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines[1].

IC50 & Target[1]

PIM1

0.24 nM (IC50)

PIM2

30 nM (IC50)

PIM3

0.12 nM (IC50)

体外研究
(In Vitro)

Uzansertib phosphate inhibits proliferation in all multiple myeloma (MM) cell lines tested, with mean GI50 values ranging from 13.2 nM to 230.0 nM in AML, MM, DLBCL, MCL, and T-ALL cell lines[1].
Uzansertib phosphate (0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM) inhibits the phosphorylation of downstream PIM kinase substrates (p70S6K/S6 and 4E-BP1) in a dose-dependent manner in MOLM-16 (AML), Pfeiffer (DLBCL), and KMS-12-PE/BM (MM) cell lines[1].
PIM kinase-mediated phosphorylation of BAD in MOLM-16 and KMS-12-BM cells is particularly sensitive to inhibition by Uzansertib phosphate (mean IC50, 4 nM and 27 nM, respectively)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Uzansertib phosphate (25-100 mg/kg; PO; twice a day; for 15 days) inhibits tumor growth in a dose-dependent manner in mice bearing MOLM-16 (AML) or KMS-12-BM (MM) [1].
Uzansertib phosphate demonstrates a dose-dependent inhibition of BAD phosphorylation relative to vehicle at 4 hours post dose (MOLM-16 tumors, IC50=70 nM; KMS-12-BM tumors, IC50=145 nM) [1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female immune compromised (severe combined immunodeficiency [SCID]) mice (5-9 weeks of age) bearing MOLM-16 (AML) or KMS-12-BM (MM)[1]
Dosage: 25, 50, 75, 100 mg/kg
Administration: PO; twice a day; for 15 days
Result: Inhibited tumor growth in a dose-dependent manner in mice.

Clinical Trial

分子量

611.51

Formula

C26H29F3N5O7P
CAS 号

2088852-47-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 5 mg/mL (8.18 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6353 mL 8.1765 mL 16.3530 mL
5 mM 0.3271 mL 1.6353 mL 3.2706 mL
10 mM — — —

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.8 mg/mL (2.94 mM); Clear solution

    此方案可获得 ≥ 1.8 mg/mL (2.94 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 18.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.8 mg/mL (2.94 mM); Clear solution

    此方案可获得 ≥ 1.8 mg/mL (2.94 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 18.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 1.8 mg/mL (2.94 mM); Clear solution

    此方案可获得 ≥ 1.8 mg/mL (2.94 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 18.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Koblish H, et al. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. PLoS One. 2018 Jun 21;13(6):e0199108.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cas(24729-96-2), Clindamycin Phosphate, 磷酸克林霉素酯,Clindamycin Phosphate,

发表于由

磷酸克林霉素酯

≥96%

有货

Cas(24729-96-2), Clindamycin Phosphate, 磷酸克林霉素酯,Clindamycin Phosphate,

CAS编号 24729-96-2 | 品牌：Jinpan
Clindamycin Phosphate

MSDS

质检证书(CoA)

相似产品

  • 分子式 C18H34ClN2O8PS
  • 分子量504.96
  • EC号 246-433-0
  • MDL号 MFCD07793328
  • PubChem编号 443385

货号 (SKU) 包装规格 是否现货 价格 数量
C129914-5g 5g 现货 Cas(24729-96-2), Clindamycin Phosphate, 磷酸克林霉素酯,Clindamycin Phosphate,  
C129914-25g 25G 现货 Cas(24729-96-2), Clindamycin Phosphate, 磷酸克林霉素酯,Clindamycin Phosphate,  
C129914-100g 100g 期货 Cas(24729-96-2), Clindamycin Phosphate, 磷酸克林霉素酯,Clindamycin Phosphate,  

基本信息

产品名称 磷酸克林霉素酯
英文名称 Clindamycin Phosphate
别名 磷酸克林霉素酯;克林霉素磷酸酯;克林霉素 磷酸盐;克林霉素 2-磷酸酯
英文别名 Clindamycin 2-Dihydrogen Phosphate;Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-(dihydrogen phosphate) Clindamycin 2-phosphate
应用 An antibiotic with anti-inflammatory properties.
规格或纯度 ≥96%
运输条件 冰袋运输
生化机理 Clindamycin Phosphate (U-28508E) is an antibiotic with anti-inflammatory properties. The compound is a potent antibiotic against anaerobic and gram-positive bacteria. Studies show that Clindamycin associates with the 50S ribosomal subunit, which leads to the inhibition of protein synthesis. Clindamycin has been used in multiple acne vulgaris studies. Clindamycin Phosphate (U-28508E) is an inhibitor of TDP1. Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria. Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

一般描述

Clindamycin Phosphate是一种林可酰胺类抗生素，作用于 Plasmodium falciparum，IC50为12 nM

Clindamycin is a lincosamide antibiotic which is considered as a semisynthetic derivative of lincomycin. It is mainly used as an antimicrobial agent.

An antibiotic with anti-inflammatory properties.

Clindamycin Phosphate is a lincosamide antibiotic for Plasmodium falciparum with IC50 of 12 nM.

Clindamycin is a lincosamide antibiotic which is considered as a semisynthetic derivative of lincomycin. It is mainly used as an antimicrobial agent.

An antibiotic with anti-inflammatory properties.

相关属性

CAS编号 24729-96-2
比旋光度 122° (C=1,H2O)
熔点 114°C
溶解性 Soluble in water, and DMSO
储存温度 2-8°C储存,充氩
RTECS GF2625000
MDL号 MFCD07793328
分子量 504.96
分子式 C18H34ClN2O8PS
EC号 246-433-0
品牌 Jinpan
PubChem CID 443385

Estramustine phosphate sodium(Synonyms: 雌莫司汀磷酸钠)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Estramustine phosphate sodium (Synonyms: 雌莫司汀磷酸钠) 纯度: 99.42%

Estramustine phosphate sodium，一种雌二醇类似物，是一种具有口服活性抗微管化疗剂。Estramustine phosphate sodium 通过与微管相关蛋白 (MAP) 和/或微管蛋白结合而使微管解聚。Estramustine phosphate sodium 可诱导前列腺癌细胞凋亡 (apoptosis)，并可用于前列腺癌的研究。

Estramustine phosphate sodium(Synonyms: 雌莫司汀磷酸钠)

Estramustine phosphate sodium Chemical Structure

CAS No. : 52205-73-9

规格 价格 是否有货 数量
10 mM * 1 mL in Water ￥660 In-stock
10 mg ￥600 In-stock
50 mg ￥990 In-stock
100 mg ￥1400 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Estramustine phosphate sodium 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Lipid Compound Library
  • Endocrinology Compound Library
  • NMPA-Approved Drug Library
  • Cytoskeleton Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library

生物活性

Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate sodium induces prostate cancer cells apoptosis and can be used for prostate cancer research[1][2].

体外研究
(In Vitro)

Estramustine phosphate sodium (1 µg/mL) treatment suppressed PC3 cell growth[2].
Estramustine phosphate sodium (2 µg/mL) treatment significantly elevates phosphatidylserine eversion amount on PC3 cells. Estramustine phosphate sodium induces PC3 cell apoptosis[2].
Estramustine phosphate sodium (2 µg/mL) treatment decreases MiR-31 level. Estramustine phosphate odium induces s prostate cancer cell line PC3 apoptosis through reducing miR-31[2].
Estramustine phosphate sodium, a unique antitumour agent, is selectively taken up by prostate cells and exerts antineoplastic effects by interfering with microtubule of dynamics and by reducing plasma levels of testosterone[1].
Estrone and estradiol, products of the metabolism of Estramustine phosphate sodium, have shown antigonadotrophic activity resulting in reduced testosterone levels similar to those achieved after surgical castration[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Estramustine phosphate sodium (4-12 mg/kg; intraperitoneal injection; daily; for 2 weeks) inhibits PAC120 tumor growth 53% by day 35[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss nu/nu (nude) male mice (5-week-old) bearing PAC120 tumors[3]
Dosage: 4 mg/kg, 12 mg/kg
Administration: Intraperitoneal injection; daily; for 2 weeks
Result: Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.

Clinical Trial

分子量

564.35

Formula

C23H30Cl2NNa2O6P
CAS 号

52205-73-9
中文名称

雌莫司汀磷酸钠；雌莫司丁磷酸钠
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro: 

H2O : 62.5 mg/mL (110.75 mM; Need ultrasonic)

DMSO : 5 mg/mL (8.86 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7720 mL 8.8598 mL 17.7195 mL
5 mM 0.3544 mL 1.7720 mL 3.5439 mL
10 mM 0.1772 mL 0.8860 mL 1.7720 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： PBS

    Solubility: 65 mg/mL (115.18 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Perry CM, et al. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49-74.

    [2]. C Wei, et al. Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels. Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):40-45.

    [3]. Bergenheim AT, et al. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet. 1998 Feb;34(2):163-72.

    [4]. Stephane Oudard, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AICAR phosphate(Synonyms: Acadesine phosphate; AICA Riboside phosphate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

AICAR phosphate (Synonyms: Acadesine phosphate; AICA Riboside phosphate) 纯度: 99.37%

AICAR phosphate (Acadesine phosphate) 是一种腺苷类似物，也是一种 AMPK 激活剂。AICAR phosphate 调节葡萄糖和脂质的代谢，并抑制促炎细胞因子和 iNOS 的产生。AICAR phosphate 也是一种自噬 (autophagy)，YAP 和 mitophagy 抑制剂。

AICAR phosphate(Synonyms: Acadesine phosphate; AICA Riboside phosphate)

AICAR phosphate Chemical Structure

CAS No. : 681006-28-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ￥572 In-stock
50 mg ￥520 In-stock
100 mg ￥860 In-stock
200 mg ￥1300 In-stock
500 mg ￥3000 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

AICAR phosphate 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Kinase Inhibitor Library
  • Metabolism/Protease Compound Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Autophagy Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Anti-COVID-19 Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Alkaloids Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Mitochondria-Targeted Compound Library
  • Transcription Factor Targeted Library
  • Lipid Metabolism Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor[1][2].

IC50 & Target[1]

AMPK

 

Autophagy

 

Mitophagy

 

Human Endogenous Metabolite

 

体外研究
(In Vitro)

HepG2 cells are treated with various concentrations of AICAR (0.1-1.0 mM) for 12, 24, and 48 h, respectively. The expression level of IR-β significantly decreases with 0.25, 0.5, and 1.0 mM of AICAR at 48 h to 50%, 53%, and 46% of the control, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Fourteen-week-old male, lean (L; 31.3 g body wt) wild-type andob/ob (O; 59.6 g body wt) mice are injected with the AMP-activated kinase (AMPK) activator AICAR (A) at 0.5 mg*g body wt-1*day-1 or saline control (C) for 14 days. At 24 h after the last injection (including a 12-h fast), all mice are killed, and the plantar flexor complex muscle (gastrocnemius, soleus, and plantaris) is excised for analysis. Muscle mass is lower in OC (159±12 mg) than LC, LA, and OA (176±10, 178±9, and 166±16 mg, respectively) mice, independent of a body weight change[3]. The kidney weight is significantly higher in the untreated group when compared with both the exercise and AICAR (0.5 mg/g body wt) groups. The heart weight is higher in the exercise group than in the other groups, whereas the liver weight is significantly higher in the AICAR-treated group when compared with the exercise and untreated groups[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

356.23

Formula

C9H17N4O9P
CAS 号

681006-28-0
中文名称

阿卡地新磷酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : 100 mg/mL (280.72 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8072 mL 14.0359 mL 28.0718 mL
5 mM 0.5614 mL 2.8072 mL 5.6143 mL
10 mM 0.2807 mL 1.4036 mL 2.8072 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Nakamaru K, et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the IR expression in HepG2 cells. Biochem Biophys Res Commun. 2005 Mar 11;328(2):449-54

    [2]. Giri S, et al. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004 Jan 14;24(2):479-87.

    [3]. Drake JC, et al. AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299(6):R1546-54.

    [4]. Pold R, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats.Diabetes. 2005 Apr;54(4):928-34.

    [5]. Ajaybabu V Pobbati, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635.
Cell Assay
[1]

HepG2 cells (5×105 cells) are plated in 6-well culture plate dishes and then are incubated in the serum-free media for 12 h before transfection. One microgram of plasmid is transfected with FuGENE6 Transfection Reagent. After 5 h of transfection, the culture media are removed and then media supplemented with or without AICAR (0.1-1.0 mM) are added to each well. The stimulation media are changed every 24 h[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2][3]

Mice[2]
Fourteen-week-old lean (Lepob/+ or Lepob/+) and ob/ob (Lepob/Lepob/) male mice are uesd. After the 14-day experimental treatment (24 h after AICAR injection, including a 12-h fast), the plantar flexor complex muscle is cleanly (tendon-to-tendon) excised from an anesthetized mouse. The muscle is quickly weighed and then processed for histology or frozen in liquid nitrogen and stored at -80°C. The anesthetized mice are killed by transection of the diaphragm and removal of the entire heart, after blood collection via needle puncture directly into the heart. AICAR or saline (control) is injected subcutaneously into the lateral distal portion of the back. AICAR is administered at 0.5 mg*g body wt-1*day-1 one time per day for 14 days. Saline (control) is injected in volumes identical to those used for AICAR treatment in a manner identical to that of AICAR treatment. Body weight is measured prior to death.
Rats[3]
Male 5-week-old ZDF rats are either subcutaneously injected with a single dose of AICAR (0.5 mg/g body wt) or underwent a single bout of treadmill running (60 min, speed of 25 m/min at a 5% incline). Untreated ZDF rats serve as controls (n=5 in each group). One hour after the subcutaneous AICAR injection or immediately after treadmill running, rats are killed by cervical dislocation. To avoid any effect of muscle spasm and hypoxia, red and white gastrocnemius muscles are removed within seconds and immediately freeze clamped for later determination of AMPK activity.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Nakamaru K, et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the IR expression in HepG2 cells. Biochem Biophys Res Commun. 2005 Mar 11;328(2):449-54

    [2]. Giri S, et al. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004 Jan 14;24(2):479-87.

    [3]. Drake JC, et al. AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299(6):R1546-54.

    [4]. Pold R, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats.Diabetes. 2005 Apr;54(4):928-34.

    [5]. Ajaybabu V Pobbati, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KN-93 phosphate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KN-93 phosphate  纯度: 99.69%

KN-93是钙离子/钙调蛋白依赖激酶II（CaMKII）抑制剂，能竞争性阻断钙调蛋白与对应激酶的结合，Ki为370 nM。

KN-93 phosphate

KN-93 phosphate Chemical Structure

CAS No. : 1913269-12-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1318 In-stock
1 mg ￥500 In-stock
5 mg ￥1000 In-stock
10 mg ￥1250 In-stock
50 mg ￥5100 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

KN-93 phosphate 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Neuronal Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library

生物活性

KN-93 phosphate is a novel membrane-permeant synthetic inhibitor of purified neuronal CaMK-II, with Ki of 370 nM.

IC50 & Target

Ki: 370 nM (CaMK-II)
体外研究
(In Vitro)

After 2 days of KN-93 treatment, 95% of cells are arrested in G1. G1 arrest is reversible; 1 day after KN-93 release, a peak of cells had progressed into S and G2-M. KN-93 also blocks cell growth stimulated by basic fibroblast growth factor, platelet-derived growth factor-BB, and epidermal growth factor in NIH 3T3 fibroblasts[1]. KN-93 inhibits the H+, K+-ATPase activity but strongly dissipates the proton gradient formed in the gastric membrane vesicles and reduces the volume of luminal space[2]. KN-93 (0.5 μM) prevents increased LV developed pressure during action potential prolongation and early afterdepolarizations. Ca2+-independent CaM kinase activity is increased during early afterdepolarizations and this increase is prevented by KN-93[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

599.03

Formula

C26H32ClN2O8PS
CAS 号

1913269-12-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (166.94 mM; Need ultrasonic)

H2O : 50 mg/mL (83.47 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6694 mL 8.3468 mL 16.6937 mL
5 mM 0.3339 mL 1.6694 mL 3.3387 mL
10 mM 0.1669 mL 0.8347 mL 1.6694 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 10 mg/mL (16.69 mM); Clear solution

    此方案可获得 ≥ 10 mg/mL (16.69 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 10 mg/mL (16.69 mM); Clear solution

    此方案可获得 ≥ 10 mg/mL (16.69 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 10 mg/mL (16.69 mM); Clear solution

    此方案可获得 ≥ 10 mg/mL (16.69 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Tombes RM, et al. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995 Sep;6(9):1063-70.

    [2]. Li J, et al. Curcumin Attenuates Retinal Vascular Leakage by Inhibiting Calcium/Calmodulin-Dependent Protein Kinase II Activity in Streptozotocin-Induced Diabetes. Cell Physiol Biochem. 2016;39(3):1196-208.

    [3]. Mamiya N, et al. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitorKN-93. Biochem Biophys Res Commun. 1993 Sep 15;195(2):608-15.

    [4]. Anderson ME, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998 Dec;287(3):996-1006.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Etoposide phosphate(Synonyms: 磷酸依托泊苷; BMY-40481)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Etoposide phosphate (Synonyms: 磷酸依托泊苷; BMY-40481) 纯度: 98.40%

Etoposide phosphate (BMY-40481) 是一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂，可以防止 DNA 链的重新连接。Etoposide phosphate 是依托泊苷的磷酸酯前药，被认为与 Etoposide 活性相当。Etoposide phosphate 诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide phosphate(Synonyms: 磷酸依托泊苷; BMY-40481)

Etoposide phosphate Chemical Structure

CAS No. : 117091-64-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ￥1177 In-stock
5 mg ￥800 In-stock
10 mg ￥1300 In-stock
25 mg ￥2600 In-stock
50 mg ￥4100 In-stock
100 mg ￥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Etoposide phosphate 相关产品

•相关化合物库:

  • Natural Product Like Compound Library
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antibacterial Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Blood Cancer Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy[1][2].

IC50 & Target[1]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule[1].
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[2].
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: FBXW+/+, FBXW-/- and p53-/- cell
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[2]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 mice[3]
Dosage: 50, 100, or 150 mg/kg
Administration: Intravenous injection; single dose
Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

分子量

668.54

Formula

C29H33O16P
CAS 号

117091-64-2
中文名称

磷酸依托泊苷
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 125 mg/mL (186.97 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4958 mL 7.4790 mL 14.9580 mL
5 mM 0.2992 mL 1.4958 mL 2.9916 mL
10 mM 0.1496 mL 0.7479 mL 1.4958 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Witterland AH, et al. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996 Oct;18(5):163-70.

    [2]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

    [3]. Bregman CL, et al. Etoposide- and BMY-40481-induced sensory neuropathy in mice.Toxicol Pathol. 1994 Sep-Oct;22(5):528-35.

    [4]. SUMMARY OF PRODUCT CHARACTERISTICS

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Etoposide phosphate disodium(Synonyms: BMY-40481 disodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Etoposide phosphate disodium (Synonyms: BMY-40481 disodium)

Etoposide phosphate disodium (BMY-40481 disodium) 是一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂，可以防止 DNA 链的重新连接。Etoposide phosphate disodium 是依托泊苷的磷酸酯前药，被认为与 Etoposide 活性相当。Etoposide phosphate disodium 诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide phosphate disodium(Synonyms: BMY-40481 disodium)

Etoposide phosphate disodium Chemical Structure

CAS No. : 122405-33-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Etoposide phosphate disodium 的其他形式现货产品:

Etoposide phosphate

生物活性

Etoposide phosphate disodium (BMY-40481 disodium) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate disodium is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate disodium induces cell cycle arrest, apoptosis, and autophagy[1][2].

IC50 & Target[2]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide phosphate disodium is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule[1].
Etoposide phosphate disodium (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[2].
Etoposide phosphate disodium (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: FBXW+/+, FBXW-/- and p53-/- cell
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[2]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 mice[3]
Dosage: 50, 100, or 150 mg/kg
Administration: Intravenous injection; single dose
Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

分子量

712.50

Formula

C29H31Na2O16P
CAS 号

122405-33-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Witterland AH, et al. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996 Oct;18(5):163-70.

    [2]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

    [3]. Bregman CL, et al. Etoposide- and BMY-40481-induced sensory neuropathy in mice.Toxicol Pathol. 1994 Sep-Oct;22(5):528-35.

    [4]. SUMMARY OF PRODUCT CHARACTERISTICS

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务